Advanced Fibrosis Detection for MASLD in Primary Care

Recruiting now · Not applicable

Conditions studied: Metabolic Dysfunction-associated Steatotic Liver Disease

In brief

This proposal evaluates the implementation of a novel, non-interruptive, electronic health record alert for metabolic dysfunction-associated steatotic liver disease (MASLD) fibrosis risk assessment in primary care patients with MASLD using a stepped wedge, cluster randomized design. This work will generate generalizable data to dramatically enhance MASLD management in primary care.

Key facts

Study ID

NCT07159386

Run by

Medical University of South Carolina

People needed

225

Starts

2026-03-16

Expected to finish

2030-09-01

Last updated by the study team

2026-03-31

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with a diagnosis code for MASLD
• Type 2 diabetes mellitus will

You may not qualify if…

• All patients with cirrhosis, complications of cirrhosis (e.g. portal hypertension, hepatic encephalopathy), hepatocellular carcinoma, or previous liver transplant will be excluded.
• pregnant women.
• Clinicians Clinicians will also be study participants, as we will be surveying them for feedback on the MASLD fibrosis risk assessment intervention. The MUSC primary care network at last count employed 122 clinicians across the 27 primary care practices.
• Inclusion criteria:
• All physicians, physician assistants, and nurse practitioners delivering primary care during the intervention phase of the study.
• Exclusion criteria:
• None

Where it is running

• Medical University of South Carolina — Charleston, South Carolina, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.